全文获取类型
收费全文 | 2350172篇 |
免费 | 171630篇 |
国内免费 | 3332篇 |
专业分类
耳鼻咽喉 | 32052篇 |
儿科学 | 75901篇 |
妇产科学 | 62726篇 |
基础医学 | 348225篇 |
口腔科学 | 63637篇 |
临床医学 | 211391篇 |
内科学 | 457335篇 |
皮肤病学 | 51732篇 |
神经病学 | 185318篇 |
特种医学 | 88027篇 |
外国民族医学 | 489篇 |
外科学 | 353906篇 |
综合类 | 47509篇 |
现状与发展 | 12篇 |
一般理论 | 848篇 |
预防医学 | 182747篇 |
眼科学 | 54325篇 |
药学 | 175138篇 |
11篇 | |
中国医学 | 4575篇 |
肿瘤学 | 129230篇 |
出版年
2021年 | 18984篇 |
2019年 | 19540篇 |
2018年 | 27065篇 |
2017年 | 20365篇 |
2016年 | 22749篇 |
2015年 | 25651篇 |
2014年 | 36102篇 |
2013年 | 53969篇 |
2012年 | 74702篇 |
2011年 | 79433篇 |
2010年 | 47063篇 |
2009年 | 44574篇 |
2008年 | 74628篇 |
2007年 | 79498篇 |
2006年 | 80313篇 |
2005年 | 77802篇 |
2004年 | 74386篇 |
2003年 | 71724篇 |
2002年 | 69388篇 |
2001年 | 108744篇 |
2000年 | 111462篇 |
1999年 | 93505篇 |
1998年 | 26997篇 |
1997年 | 23661篇 |
1996年 | 24057篇 |
1995年 | 22716篇 |
1994年 | 20898篇 |
1993年 | 19717篇 |
1992年 | 72006篇 |
1991年 | 70072篇 |
1990年 | 68397篇 |
1989年 | 65666篇 |
1988年 | 60307篇 |
1987年 | 59129篇 |
1986年 | 55221篇 |
1985年 | 53005篇 |
1984年 | 39313篇 |
1983年 | 33399篇 |
1982年 | 19859篇 |
1979年 | 35869篇 |
1978年 | 25651篇 |
1977年 | 21230篇 |
1976年 | 20334篇 |
1975年 | 21818篇 |
1974年 | 26149篇 |
1973年 | 24803篇 |
1972年 | 23201篇 |
1971年 | 22041篇 |
1970年 | 20248篇 |
1969年 | 19316篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
941.
A J Armengol C R Brohet J P Lintermans A Vliers 《Archives des maladies du coeur et des vaisseaux》1987,80(4):445-453
The electrocardiographic features of Noonan's syndrome have been known for several years, but the discordance between these electrical findings and the underlying haemodynamic disorders remains unexplained. In an attempt to elucidate the genesis of electrical abnormalities, we present here a retrospective study of 14 children with Noonan's disease, aged from a few days to 16 years and evaluated by electrocardiography, vectography, one- or two-dimensional echocardiography, angiography and His bundle electrophysiology. The electrocardiographic abnormalities observed concerned ventricular depolarization and intracardiac electric conduction with, notably, a QRS axis directed towards the right upper part of the electric field and a first degree infra-hisian atrioventricular block (His bundle potentials). Vectography showed in some cases an image of inferior pseudo-necrosis due to the absence of initial inferior forces; this image is highly characteristic. In other cases the QRS loop showed an image of left segmental block which is unusual in this type or cardiac pathology (pulmonary stenosis with or without atrial septal defect of the ostium secundum type). 相似文献
942.
Characterization of gp 50, a major glycoprotein present in rat brain synaptic membranes, with a monoclonal antibody 总被引:4,自引:0,他引:4
Philip W. Beesley Toni Paladino Claude Gravel Richard A. Hawkes James W. Gurd 《Brain research》1987,408(1-2):65-78
Several cell lines secreting monoclonal antibodies (Mabs) against a major forebrain synaptic membrane (SM) glycoprotein, gp 50, have been raised. Western blots show that the Mabs react with a polypeptide doublet of Mrs 49 and 45 kDa. These polypeptides exist solely in a concanavalin A (Con A) binding form. Removal of the Con A receptors by digestion with endo-beta-N-acetylglucosaminidase H (endo H) lowers the Mrs of the glycoprotein doublet to 36.5 and 34 kDa. Western blots of 2D polyacrylamide gels indicate that gp 50 exists in several isoforms. Solid phase radioimmunoassay (RIA) and Western blots of brain subcellular fractions show the antigenic material to be concentrated in the SM fraction, but to be present in much lower amounts in synaptic junctions and postsynaptic densities. Gp 50 appears to be brain specific. Regional distribution studies show that it is present in all brain regions but is two-fold concentrated in cerebellum, brainstem and midbrain compared to forebrain. Immunocytochemical studies of several brain regions show that gp 50-like immunoreactivity is neuron specific and is concentrated in selected neuronal species, particularly granule cells. In both cerebellar and hippocampal granule cells gp 50-like immunoreactivity is localized in the perikarya and primary dendrites. Though immunocytochemistry did not show staining of synaptic regions this may be due to masking of the reactive epitope. The results are discussed in terms of the molecular properties of gp 50 and its subcellular localization in brain tissue. 相似文献
943.
944.
945.
946.
947.
3-(Methylnitrosamino)propionitrile: occurrence in saliva of betel quid chewers, carcinogenicity, and DNA methylation in F344 rats 总被引:1,自引:0,他引:1
3-(Methylnitrosamino)propionitrile (MNPN), a potent carcinogen in F344 rats, was detected for the first time in the saliva of betel quid chewers at levels ranging from 0.5 to 11.4 micrograms/liter. The tumorigenic properties of MNPN and its potential to methylate DNA in F344 rats were evaluated. Groups of 21 male and 21 female rats were given 60 s.c. injections over a 20-week period (total doses 0.055 and 0.23 mmol per rat). The experiment was terminated after 106 weeks. MNPN at the higher dose induced 18 (86%) malignant tumors of the nasal cavity in male and 15 (71%) in female rats. The lower dose induced nine (43%) liver tumors. Groups of four or five male F344 rats were treated with a single s.c. or i.v. injection of MNPN (0.4 mmol/kg). MNPN was also administered to rats by swabbing the oral cavity (2.21 mmol/kg). The levels of 7-methylguanine and O6-methylguanine, formed 0.5-36 h after treatment, were measured in the liver, nasal mucosa, esophagus, and oral issues. The highest levels of methylated guanines were detected in the nasal cavity independent of the route of administration. The results of this study demonstrate that MNPN is present in the saliva of betel quid chewers and is a potent carcinogen in F344 rats. 相似文献
948.
Pharmacokinetic interactions of cimetidine 1987 总被引:4,自引:0,他引:4
The number of studies on drug interactions with cimetidine has increased at a rapid rate over the past 5 years, with many of the interactions being solely pharmacokinetic in origin. Very few studies have investigated the clinical relevance of such pharmacokinetic interactions by measuring pharmacodynamic responses or clinical endpoints. Apart from pharmacokinetic studies, invariably conducted in young, healthy subjects, there have been a large number of in vitro and in vivo animal studies, case reports, clinical observations and general reviews on the subject, which is tending to develop an industry of its own accord. Nevertheless, where specific mechanisms have been considered, these have undoubtedly increased our knowledge on the way in which humans eliminate xenobiotics. There is now sufficient information to predict the likelihood of a pharmacokinetic drug-drug interaction with cimetidine and to make specific clinical recommendations. Pharmacokinetic drug interactions with cimetidine occur at the sites of gastrointestinal absorption and elimination including metabolism and excretion. Cimetidine has been found to reduce the plasma concentrations of ketoconazole, indomethacin and chlorpromazine by reducing their absorption. In the case of ketoconazole the interaction was clinically important. Cimetidine does not inhibit conjugation mechanisms including glucuronidation, sulphation and acetylation, or deacetylation or ethanol dehydrogenation. It binds to the haem portion of cytochrome P-450 and is thus an inhibitor of phase I drug metabolism (i.e. hydroxylation, dealkylation). Although generally recognised as a nonspecific inhibitor of this type of metabolism, cimetidine does demonstrate some degree of specificity. To date, theophylline 8-oxidation, tolbutamide hydroxylation, ibuprofen hydroxylation, misonidazole demethylation, carbamazepine epoxidation, mexiletine oxidation and steroid hydroxylation have not been shown to be inhibited by cimetidine in humans but the metabolism of at least 30 other drugs is affected. Recent evidence indicates negligible effects of cimetidine on liver blood flow. Cimetidine reduces the renal clearance of drugs which are organic cations, by competing for active tubular secretion in the proximal tubule of the kidney, reducing the renal clearances of procainamide, ranitidine, triamterene, metformin, flecainide and the active metabolite N-acetylprocainamide. This previously unrecognised form of drug interaction with cimetidine may be clinically important for both parent drug, and metabolites which may be active.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
949.
G Pelletier A M de Passillé M Bernier-Cardou J Morisset 《The Journal of nutrition》1987,117(10):1759-1766
In the first experiment, 52 sows, each having raised one litter, were randomly assigned to the five following groups: control (nongravid) for pregnancy (CP), 110 d pregnancy (P110), control (nongravid) for lactation (CL), 4-wk lactation with 8 (L8) and with 12 (L12) piglets. In a second experiment, 36 sows, each having raised three litters, were randomly assigned to the following groups: control group (nongravid) fed a low-energy-density, 1% tallow diet (CLED) and two lactating groups, one fed the low-energy-density diet (LLED) and one fed a high-energy-density, 10% tallow diet (LHED). At slaughter, the stomach, small and large intestine and cecum were excised, emptied and freed from fat. Lengths and pre- and post-defatting weights were measured. Portions of tissues were homogenized and analyzed for protein, pepsin, maltase, RNA and DNA. Pregnancy had no effect on the weights of the different components of the gastrointestinal tract. Liver and small intestine weights were larger in lactating sows than in the CL group. Sows nursing 12 piglets had heavier livers than those nursing 8. The fundic mucosa of the latter had higher total pepsin activity and total protein and RNA contents than that of L12 sows. LHED sows had heavier small intestine and lower total pepsin content of the fundic mucosa than LLED sows. 相似文献
950.